Shares of Regulus Therapeutics RGLS fell in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 65.22% year over year to ($0.08), which were in line with the estimate of ($0.08).
Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $10,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 10, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/xnw8bbur
Technicals
52-week high: $2.32
52-week low: $0.42
Price action over last quarter: down 18.18%
Company Overview
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
